Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

BASF Chooses IDBS for Data Management

May 10, 2011 11:29 am | News | Comments

IDBS announced that BASF has selected IDBS to deliver a data management and process development platform across its global research organization.


Sistemic And Roslin Working Together on Stem Cells

May 10, 2011 11:25 am | News | Comments

Sistemic Ltd and Roslin Cells Ltd signed a Memorandum of Understanding to promote the development of new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening.


LIMS Software

May 10, 2011 11:19 am | Product Releases | Comments

GenoLogics announced its updated LIMS, designed to provide the features necessary for mainstream adoption of the most advanced sequencing technologies while supporting existing genotyping platforms.


RNA Reagent

May 10, 2011 11:11 am | Product Releases | Comments

Honeywell announced the introduction of an RNA reagent for use in developing advanced therapeutic medicines. The Burdick & Jackson rBMI activator, is designed to help laboratories reduce the use of costly amidites.


Talon Begins Phase 3 Lymphoma Trial

May 10, 2011 11:05 am | News | Comments

Talon Therapeutics, Inc. announced the initiation of a Phase 3 Study of Marqibo in elderly patients with newly diagnosed aggressive Non-Hodgkin's Lymphoma to be conducted by the German High-Grade Non-Hodgkin's Lymphoma Study Group.


Nymox Recruiting for Late-stage BPH Study

May 10, 2011 10:54 am | News | Comments

Nymox Pharmaceutical Corporation announced that recruitment will begin for NX02-0020, a small open-label short-term safety study of NX-1207, the company's Phase 3 drug for benign prostatic hyperplasia.


USPTO Grants Odyssey New Patent

May 10, 2011 10:50 am | News | Comments

Odyssey Thera, Inc. announced that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."


FDA Approves Affymetrix Reagents

May 10, 2011 10:48 am | News | Comments

Affymetrix, Inc. announced that the U.S. Food and Drug Administration has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic (IVD) use.


Humira Performs Well in Colitis Trial

May 10, 2011 10:42 am | News | Comments

Abbott Laboratories said its drug Humira met key treatment goals in a late-stage study focusing on ulcerative colitis. Ulcerative colitis is a chronic inflammatory bowel disease affecting nearly 700,000 people in the U.S.


FDA Fast Tracking Regorafenib

May 10, 2011 10:34 am | News | Comments

Bayer HealthCare Pharmaceuticals Inc. said that the Food and Drug Administration will conduct a fast track review of its cancer drug candidate regorafenib.


Avanir Loss Grows in 2Q

May 10, 2011 10:29 am | News | Comments

Avanir Pharmaceuticals Inc. reported a bigger loss for its fiscal second quarter due to costs to launch the drug Nuedexta. Nuedexta is the first and only FDA-approved treatment for pseudobulbar affect.


Remicade Meets UC Study Goals

May 10, 2011 10:23 am | News | Comments

Johnson & Johnson said that its drug Remicade met key goals in treating pediatric patients with moderate to severe ulcerative colitis in a late-stage study.


DavosPharma to Market Immunologix’s Antbodies

May 10, 2011 8:05 am | News | Comments

Immunologix, Inc., Charleston, S.C., and DavosPharma, Upper Saddle River, N.J. have formed a strategic alliance whereby DavosPharma, a provider of discovery, chemistry, and formulation services, will represent and market 100% human antibodies produced by Immunologix.


OncoGenex provided an update on recent drug development and clinical trial activities

May 10, 2011 8:00 am | News | Comments

The company is currently enrolling a Phase 3 clinical trial referred to as SYNERGY, to be conducted in approximately 123 cancer centers to evaluate a survival benefit for custirsen in combination with first-line docetaxel treatment in approximately 800 patients with castration-resistant prostate cancer (CRPC).


OGI Genomics Researchers Awarded $23 million

May 10, 2011 7:49 am | News | Comments

The Ontario Genomics Institute (OGI) has been awarded $23.8 million to support genomics research. $11.3 million from Genome Canada and $12.5 million from co-funding.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.